Title : Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.

Pub. Date : 2020 May

PMID : 31931137






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 INTRODUCTION: Limited clinical data are available regarding the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations. Tyrosine epidermal growth factor receptor Homo sapiens